Humanized vs Fully Human Antibodies: Which Is Right for Your Pipeline?
A humanized antibody contains 90–95% human protein sequences. Fully human antibodies frequently reduce clinical risk. Lower immunogenicity can improve patient retention and minimize trial delays caused by immune related adverse events.













